Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I. Sherman

Showing results (101-110 of 141) with videos related to

Pageof 15
Sort By:
Head & Neck|February 14, 2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profilingSaad A Khan, Bo Ci, Yang Xie, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2009
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, David S Cooper, Gerard M Doherty, et al.
Thyroid : Official Journal of the American Thyroid Association|January 4, 2007
Outcomes of patients with differentiated thyroid carcinoma following initial therapyJacqueline Jonklaas, Nicholas J Sarlis, Danielle Litofsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalHeribert Hänscheid, Michael Lassmann, Markus Luster, et al.
Thyroid : Official Journal of the American Thyroid Association|June 5, 2013
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosisDonald S A McLeod, David S Cooper, Paul W Ladenson, et al.
Thyroid : Official Journal of the American Thyroid Association|September 24, 2009
Recurrence after treatment of micropapillary thyroid cancerDouglas S Ross, Danielle Litofsky, Kenneth B Ain, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancerBradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Lancet (London, England)|April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialMarcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Journal of the Endocrine Society|April 25, 2024
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease AggressivenessAditya S Shirali, Mimi I Hu, Yi-Ju Chiang, et al.
Pageof 15

Showing results (101-110 of 141) with videos related to

Sort By:
Pageof 15
Head & Neck|February 14, 2019
Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profilingSaad A Khan, Bo Ci, Yang Xie, et al.
Thyroid : Official Journal of the American Thyroid Association|October 29, 2009
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, David S Cooper, Gerard M Doherty, et al.
Thyroid : Official Journal of the American Thyroid Association|January 4, 2007
Outcomes of patients with differentiated thyroid carcinoma following initial therapyJacqueline Jonklaas, Nicholas J Sarlis, Danielle Litofsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawalHeribert Hänscheid, Michael Lassmann, Markus Luster, et al.
Thyroid : Official Journal of the American Thyroid Association|June 5, 2013
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosisDonald S A McLeod, David S Cooper, Paul W Ladenson, et al.
Thyroid : Official Journal of the American Thyroid Association|September 24, 2009
Recurrence after treatment of micropapillary thyroid cancerDouglas S Ross, Danielle Litofsky, Kenneth B Ain, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesDavid S Hong, Maria E Cabanillas, Jennifer Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancerBradley A Schiff, Andrea B McMurphy, Samar A Jasser, et al.
Lancet (London, England)|April 29, 2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialMarcia S Brose, Christopher M Nutting, Barbara Jarzab, et al.
Journal of the Endocrine Society|April 25, 2024
Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease AggressivenessAditya S Shirali, Mimi I Hu, Yi-Ju Chiang, et al.
Pageof 15